Fig. 2
Effect of tolvaptan 15, 30 and 45 mg at baseline, during and after NO-inhibition on FENa (e) and u-ENaCγ (f). Data are presented as mean ± SEM. General linear model (GLM) with repeated measures was performed for comparison within and between groups. One-way ANOVA (*) was used to test differences between tolvaptan 15, 30 and 45 mg vs placebo. Paired t-test (α/β/γ) was used for comparison of infusion period (90–150 min) vs baseline period (0–90 min) and post infusion period (150–210 min) vs baseline period. † p<; 0.05; †† p < 0.001; */††† p < 0.0001. Paired t-test was used for comparison between the three tolvaptan doses at baseline period (0–90 min), L-NMMA infusion period (90–150 min) and post infusion period (150–210 min); the significance levels are listed under the result section